Last reviewed · How we verify
Docetaxel + Standard dose Vitamin D2
Docetaxel stabilizes microtubules to inhibit cancer cell division, while vitamin D2 may enhance immune function and potentially reduce docetaxel toxicity.
Docetaxel stabilizes microtubules to inhibit cancer cell division, while vitamin D2 may enhance immune function and potentially reduce docetaxel toxicity. Used for Solid tumors (specific indication under investigation in phase 3 trial at King Faisal Specialist Hospital & Research Center).
At a glance
| Generic name | Docetaxel + Standard dose Vitamin D2 |
|---|---|
| Sponsor | King Faisal Specialist Hospital & Research Center |
| Drug class | Taxane chemotherapy + vitamin supplement |
| Target | β-tubulin (docetaxel); vitamin D receptor (vitamin D2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Docetaxel is a taxane that binds to β-tubulin and prevents microtubule depolymerization, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Vitamin D2 (ergocalciferol) is added as a potential adjunctive agent to modulate immune response and possibly mitigate chemotherapy-related adverse effects, though the synergistic benefit in this combination requires clinical validation.
Approved indications
- Solid tumors (specific indication under investigation in phase 3 trial at King Faisal Specialist Hospital & Research Center)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Peripheral neuropathy
- Fatigue
- Nausea/vomiting
- Alopecia
- Hypersensitivity reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: